Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
阿瓦洛治疗公司(纳斯达克代码:AVTX-GET评级)在10月份看到空头股数的销售额大幅下降。截至10月31日,空头股数共有35,300股,较10月15日的48,700股下降了27.5%。以日均成交量31,100股计算,目前短息比率为1.1天。目前,该公司0.4%的股票被卖空。
Avalo Therapeutics Trading Down 0.5 %
Avalo治疗公司股价下跌0.5%
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
在周一的交易中,纳斯达克AVTX股价下跌0.03美元,至5.77美元。该公司股票的成交量为6,065股,而其平均成交量为41,556股。该公司的债务权益比为5.23,流动比率为1.07,速动比率为0.97。该业务的50日简单移动均线切入位为4.92美元,200日简单移动均线切入位为5.19美元。Avalo Treateutics的股价为52周低点2.42美元,52周高点27.84美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
另外,奥本海默在11月9日星期三的一份报告中将Avalo治疗公司的目标价从17.00美元下调至10.00美元。
Institutional Investors Weigh In On Avalo Therapeutics
机构投资者看好Avalo治疗公司
About Avalo Therapeutics
关于Avalo Treateutics
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家临床阶段的精密药物公司,为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002,这是一种完全人类抗光的单抗,正在进行第二阶段临床试验,用于治疗非嗜酸性哮喘以及炎症性肠道疾病,包括中到重度克罗恩病和溃疡性结肠炎;以及第三阶段临床试验,用于治疗新冠肺炎急性呼吸窘迫综合征。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- 是时候与Joby Aviation的电动汽车创新一起兜风了吗?
- 在100美元的理发之后,Catalent是一个超卖的制药公司吗?
- 泰森食品是不是太便宜了,不容忽视?
- Alphabet股票提供难得的买入机会
- 太阳能电池制造商安相清理买入点位:涨势能否守住?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。